Gavestinel

Key Product Details

Product Description

Gavestinel is a highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (K_d = 0.8 nM). Displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites. Orally bioavailable and active in vivo.

Licensing Information

Sold with the permission of GlaxoSmithKline

Product Specifications for Gavestinel

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Gavestinel

The following data is based on the product molecular weight 397.19.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.4 mM	6.29 mL	31.47 mL	62.94 mL
2 mM	1.26 mL	6.29 mL	12.59 mL
4 mM	0.63 mL	3.15 mL	6.29 mL
20 mM	0.13 mL	0.63 mL	1.26 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 8 publications citing the usage of this product.

• Mugnaini Receptor binding characteristics of the novel NMDA receptor glycine site antagonist [³H]GV150526A in rat cerebral cortical membranes. Eur.J.Pharmacol. 2000 PMID: 10729363
• Kajbaf Pharmacokinetics, metabolism and excretion of the glycine antagonist GV150526A in rat and dog. Xenobiotica. 2003 PMID: 12745876
• Di Fabio Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. J.Med.Chem. 1997 PMID: 9083472

Product Documents for Gavestinel